Tecovirimat

DB12020ApprovedInvestigationalSmall moleculeOrthopoxvirus VP37 Envelope Wrapping Protein Inhibitor

Tecovirimat is an antiviral medication used to treat smallpox, monkeypox, and cowpox. The World Health Organization declared smallpox, a contagious and sometimes fatal infectious disease, eradicated in 1980.

Chemical structure of Tecovirimat
Mechanism
Curator reviewed · 10 references
Primary indication
Tecovirimat is an inhibitor of the orthopoxvirus VP37 envelope wrapping protein and is indicated for the treatment of human smallpox disease in adults and pediatric patients weighing at least 3 kg.Curator reviewed · 5 structured indications
Formula / weight
C19H15F3N2O3 · 376.335 g/mol (avg)
First approval
Canada, 2021 · United States, 2018 · European Union, 2022
Code names
SIGA-246 · ST-246
Brand names
  • Tecovirimat Siga
  • Tpoxx

Resolves to

Structure
InChIKeyCSKDFZIMJXRJGH-VWLPUNTISA-NSMILESFC(F)(F)C1=CC=C(C=C1)C(=O)NN1C(=O)[C@H]2[C@H]([C@H]3C=C[C@@H]2[C@@H]2C[C@H]32)C1=O
Transporters

What you can answer from here — as of September 23, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
1TransporterSubstrate / inhibitor direction, not just membership
Listed above
401Drug interactionsStructured to mechanism, not free text
Sign in
16Clinical trialsPhase, status and sponsor resolved per trial
Sign in
5Structured indicationsCondition, population, route and combination as fields, not prose
Sign in
2ContraindicationsEach with its own population and attribute set
Sign in
5Marketed productsAcross 4 countries and 1 labeller
Sign in
1ATC codeIncluding every combination product, plus 30 drug categories
Sign in
30+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Tecovirimat, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.

Create Account